石家庄以岭药业股份有限公司 2025 年半年度报告全文 石家庄以岭药业股份有限公司 2025 年半年度报告 股票代码：002603 股票简称：以岭药业 披露日期：2025 年 8 月 28 日 1 石家庄以岭药业股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 公司负责人吴相君、主管会计工作负责人李晨光及会计机构负责人（会计主管人员） 蔡丽琴声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 公司已在本报告中描述了公司可能面临的相关风险，请查阅本报告第三节之"管理层 讨论与分析"中相应内容，敬请广大投资者注意投资风险。 公司经本次董事会审议通过的利润分配预案为：以 2025 年 6 月 30 日总股本 1,670,705,376 为基数，向全体股东每 10 股派发现金红利 3.00 元（含税），送红股 0 股（含 税），不以公积金转增股本。 2 | | | | 第一节 | 重要提示、目录 ...

石家庄以岭药业股份有限公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 单位：万元 非经营性资金 占用 资金占用方名称 占用方与上市 公司的关联关 系 上市公司核 算的会计科 目 2025 年期初 占用资金余 额 2025 年半年度 占用累计发生 金额（不含利 息） 2025 年半年 度占用资金的 利息（如有） 2025 年半年 度偿还累计 发生金额 2025 年半年 度期末占用 资金余额 占用形成原 因 占用性质 控股股东、实 际控制人及其 附属企业 非经营性占用 小计 - - - - 前控股股东、 实际控制人及 其附属企业 非经营性占用 小计 - - - - 其他关联方及 其附属企业 非经营性占用 小计 - - - - 总计 - - - - 其他关联资金 往来 资金往来方名称 往来方与上市 公司的关联关 系 上市公司核 算的会计科 目 2025 年半年 度期初往来 资金余额 2025 年半年度 往来累计发生 金额（不含利 息） 2025 年半年 度往来资金的 利息（如有） 2025 年半年 度偿还累计 发生金额 2025 年半年 度期末往来 资金余额 往来形成原 因 往来性质 （经营性 ...

石家庄以岭药业股份有限公司 2025 年半年度报告全文 石家庄以岭药业股份有限公司 2025 年半年度财务报告 股票代码：002603 股票简称：以岭药业 1 石家庄以岭药业股份有限公司 2025 年半年度报告全文 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 编制单位：石家庄以岭药业股份有限公司 2025 年 06 月 30 日 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 1,040,200,332.52 | 853,034,839.38 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | 560,500,000.00 | | | 衍生金融资产 | | | | 应收票据 | | | | 应收账款 | 1,399,916,419.19 | 1,225,430,236.42 | | 应收款项融资 | 556,230,883.96 | 164,679,389.78 | | 预付款项 | 69,036 ...

Core Viewpoint - The newly released guideline recommends the innovative traditional Chinese medicine, Shen Song Yang Xin Capsule, for the management of atrial fibrillation (AF), marking a significant milestone in integrating traditional Chinese medicine into modern cardiovascular treatment [1][2][14]. Group 1: Guideline Development and Significance - The guideline was developed by 67 experts from various medical associations, incorporating recent research and consensus on atrial fibrillation management [1]. - It emphasizes a comprehensive management approach for AF, integrating prevention, acute treatment, and long-term follow-up, highlighting the importance of multidisciplinary collaboration [2][3]. Group 2: Clinical Evidence and Recommendations - Shen Song Yang Xin Capsule is recommended for maintaining sinus rhythm in paroxysmal AF patients and reducing recurrence rates in patients post-radiofrequency ablation [1][4]. - The capsule's efficacy was supported by a multi-center randomized controlled trial involving 349 patients, showing a total effective rate of 62.3%, comparable to the drug Propafenone [5][7]. Group 3: Mechanism and Unique Advantages - The capsule operates through a unique formulation that addresses both rapid and slow heart rhythms, making it particularly suitable for elderly patients who may experience both types of arrhythmias [9][12]. - Its mechanism includes regulating ion channels and autonomic nervous functions, which helps improve cardiac conduction and stabilize heart rates [10][11]. Group 4: Future Implications and Research Directions - The inclusion of Shen Song Yang Xin Capsule in the guideline is expected to enhance the treatment options available for AF, particularly in the context of post-ablation management [14][15]. - Experts advocate for further high-quality clinical research to validate the efficacy of traditional Chinese medicine in treating arrhythmias, aiming for broader acceptance and integration into global treatment protocols [15][16].

Investment Rating - The investment rating for the industry is "Positive" and is maintained [8]. Core Insights - The innovation layout of traditional Chinese medicine (TCM) companies includes two main categories: (1) TCM new drugs primarily classified as Class 1, which cannot currently use the same valuation system as innovative drugs due to differences in input-output, release rhythm, and lifecycle; (2) Innovative chemical and biological drugs, which are in need of value reassessment within TCM companies [2][6]. - The approval of TCM new drugs is accelerating, but the industry is still in its early development stage. From 2017 to 2024, the approval of TCM new drugs shows an accelerating trend, and with the implementation of policies and active corporate layouts, a surge in TCM new drug listings is expected [6][17]. - Several TCM companies are actively laying out innovative chemical and biological drugs, with companies like Jiuzi Tang, Kangyuan Pharmaceutical, Yiling Pharmaceutical, and Tianshili having multiple pipelines entering clinical stages, laying a solid foundation for long-term development [6][21]. Summary by Sections TCM New Drug Approval - The approval of TCM new drugs is showing an accelerating trend, indicating a potential future surge in listings due to supportive policies and active corporate strategies [6][17]. - The industry is still considered to be in its early development stage, with a different valuation system compared to chemical and biological drugs [6][17]. Innovative Drug Layout of TCM Companies - TCM companies are increasingly involved in the layout of innovative chemical and biological drugs, with several companies having multiple pipelines in clinical stages [21][22]. - Specific companies such as Jiuzi Tang focus on stem cell drugs, while Kangyuan Pharmaceutical has several pipelines in late-stage clinical trials for major diseases [21][22]. - Yiling Pharmaceutical has innovative chemical drugs entering the harvest stage, and Tianshili is involved in various fields including dual antibodies and stem cell injections [21][22]. Investment Perspective - The report suggests that the "insurance fund's transformation" will continue to evolve, with innovative drugs being a primary investment focus. Companies with healthy cash flow and innovative capabilities are favored [28]. - The report emphasizes the importance of breakthrough therapies and technological advancements, particularly in new treatment areas such as cytokine immunotherapy and PD1-based therapies [28].

当今世界，可持续发展已成为全球共识，而中国正以高质量发展为引领，探索一条具有中国特色的ESG实践之路。观察者网始终秉持"全球视野，中国关 怀"的立场，既关注国际可持续发展趋势，更重视本土化实践创新。 一个优秀的企业，他不仅仅是在生产、经营等企业活动中做到了行业的典范。同时他还担负起了应有的社会责任，或环境、或社会、或企业治理，你所关 注的每一个正义事业，都是优秀企业积极推动人类社会文明向前价值所在。而这也是观察者网的价值观所在，我们关注优秀的企业，并致力同优秀企业共 同成长。同时我们也高度关注后发企业，积极出谋划策，为后发企业变得更强贡献己所能及的力量。 观察者网自去年成功发起首届 "《高质量发展下的ESG》—2024 ESG典范企业评选榜单"评选后，获得了产业界、学术界以及企业伙伴的广泛关注与积极 反响。首届评选不仅成功挖掘出一批将ESG理念深度融入公司战略、引领行业绿色变革的标杆企业，也为公众理解ESG在中国本土实践中的内涵提供了重 要视角，推动了ESG从"概念"走向"行动"的共识。 承继首届成功经验，历经数月的筹备与评审，观察者网今日正式发布《2025观察者网ESG"典范企业"评选榜单》。本届评选在标准 ...

Core Insights - Yiling Pharmaceutical has achieved significant innovation milestones in 2025, including the acceptance of its first classic prescription product, Banxia Baizhu Tianma Granules, and the approval for clinical trials of the chemical drug G201-Na Capsule [1] - The company has successfully launched Qifang Bitong Tablets in both domestic and Macau markets, indicating a potential expansion in sales [1] Group 1: Innovation and Product Development - Yiling Pharmaceutical is a leading representative in the modernization of traditional Chinese medicine, operating in three main business segments: traditional Chinese medicine, chemical medicine, and health products [2] - The company has launched 17 patented traditional Chinese medicines, covering eight major clinical disease systems, with 11 products included in the national medical insurance catalog [2] - From 2020 to 2024, Yiling Pharmaceutical has developed five new drugs, averaging one new drug per year, which is notable compared to the national average of fewer than 10 new traditional Chinese medicines approved annually [2] Group 2: Research and Development Pipeline - The company has a robust pipeline of research projects, with two traditional Chinese medicines approved for production, six in clinical trial phases, and over a hundred hospital preparations as reserves for new drug development [5] - A detailed list of ongoing research projects includes various traditional Chinese medicines targeting conditions such as allergic rhinitis, chronic cholecystitis, and pediatric colds, with several in different stages of clinical trials [3][4] Group 3: Strategic Expansion and Internationalization - Yiling Pharmaceutical is focusing on high-quality development by increasing innovation investments and accelerating high-end and international industrial layouts, aiming to create a globally influential industrial cluster [6] - The company's core products are now available in over 50 countries and regions, reflecting its solid internationalization efforts [6] - Yiling has developed a unique theory system on "Luo Disease," which has gained international recognition, and has published the first English textbook on this subject, further promoting traditional Chinese medicine globally [6]

中国工程院2025年院士增选提名工作已经结束。经中国工程院第八届主席团第十六次会议审议，中国工 程院党组审定，确认中国工程院2025年院士增选有效候选人660人。其中，机械与运载工程学部68人， 信息与电子工程学部68人，化工、冶金与材料工程学部71人，能源与矿业工程学部72人，土木、水利与 建筑工程学部91人，环境与轻纺工程学部73人，农业学部83人，医药卫生学部91人，另有特别通道43 人。 8月20日，中国科学院、中国工程院公布2025年院士增选有效候选人名单。 此次进入2025年院士增选有效候选人名单的企业高层分别为中国科学院院士增选有效候选人：香港中文 大学（深圳）国际眼科研究所林顺潮，推荐人陈春英、杨焕明；北京脑科学与类脑研究所罗敏敏，推荐 人时松海、叶玉如。 （文章来源：华夏时报） 中国工程院2025年院士增选有效候选人：上海芯超生物科技有限公司郜恒骏，推荐人樊代明；中国科学 院上海药物研究所耿美玉，推荐人丁健；石家庄以岭药业股份有限公司贾振华，推荐人田金洲；深圳华 大科技控股有限公司徐讯，推荐人乔杰。 2025年中国科学院院士增选推荐工作已经结束。经中国科学院学部主席团审议，中国科学院党组审定 ...

Group 1 - The 2025 academician election for the Chinese Academy of Sciences (CAS) has confirmed 639 valid candidates across various disciplines, including 98 in Mathematics and Physics, 105 in Chemistry, 125 in Life Sciences and Medicine, 96 in Earth Sciences, 61 in Information Technology, 104 in Engineering Technology, and 50 in special recommended fields [2] - The Chinese Academy of Engineering (CAE) has confirmed 660 valid candidates for the 2025 academician election, with representation from Mechanical and Transportation Engineering (68), Information and Electronic Engineering (68), Chemical, Metallurgical and Materials Engineering (71), Energy and Mining Engineering (72), Civil, Hydraulic and Architectural Engineering (91), Environmental and Light Textile Engineering (73), Agricultural (83), Medical and Health (91), and 43 in special channels [3] - The election for academicians occurs every two years, with the 2025 election process having started on April 25, and each academy having a limit of no more than 100 new academicians [3]

Group 1 - The core viewpoint of the article is that Jihong Co., Ltd. reported significant growth in its mid-year performance for 2025, with a notable increase in both revenue and net profit [1] - The company's operating revenue reached approximately 3.234 billion yuan, representing a year-on-year growth of 31.79% [1] - The net profit attributable to shareholders was about 118 million yuan, showing a year-on-year increase of 63.27% [1] - The basic earnings per share were reported at 0.3 yuan [1] Group 2 - The revenue growth was primarily driven by an increase in income from cross-border e-commerce and packaging business [1]